MedTrace Logo

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

NCT05682638 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34000

Last updated 2023-02-21

No results posted yet for this study

Summary

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Older

Conditions

Interventions

BIOLOGICAL

LVRNA009

100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart

OTHER

0.9%NaCl

1.0ml/dose, 2 injection with 28 days apart

Sponsors & Collaborators

  • AIM Innovation Biotechnology (Shanghai) Co., Ltd

    collaborator UNKNOWN

  • Ningbo Rongan Biological Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • LiveRNA Therapeutics Inc.

    collaborator UNKNOWN

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682638 on ClinicalTrials.gov